Antimalarial Drugs and COVID -19

BUILDERS, Modupe I.; SIMEON, Joseph Oyepata; OGUNDEKO, Timothy Olugbenga; BUILDERS, Philip

dc.contributor.author	BUILDERS, Modupe I.
dc.contributor.author	SIMEON, Joseph Oyepata
dc.contributor.author	OGUNDEKO, Timothy Olugbenga
dc.contributor.author	BUILDERS, Philip
dc.date.accessioned	2021-12-03T12:27:07Z
dc.date.available	2021-12-03T12:27:07Z
dc.date.issued	2020
dc.identifier.issn	663-421X
dc.identifier.uri	http://localhost:8080/xmlui/handle/123456789/664
dc.description.abstract	The coronavirus disease 2019 (COVID-19) is a novel virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that is ravaging the world. Therefore, the need to find new preventive and therapeutic drug at the earliest possible time additionally to the implementation of preventive measures such as early detection, isolation and treatment of cases as well as minimization of transmission through physical interaction. Moreover, specific vaccines and yet effective treatment that target the 2019. This review focuses on the use of antimalarial drugs as therapeutics interventions for COVID-19.	en_US
dc.language.iso	en	en_US
dc.publisher	SUMERIANZ JOURNAL OF MEDICAL AND HEALTHCARE (SJMH) Vol. 3 No. 12	en_US
dc.subject	COVID-19	en_US
dc.subject	SARS-CoV-2	en_US
dc.title	Antimalarial Drugs and COVID -19	en_US
dc.type	Article	en_US